A secondary analysis of the HERA trial showed that a subgroup of patients with ER+/HER2+ breast cancer, with lower HER2 FISH ratios or higher ESR1 mRNA expression, got less benefit from the addition of adjuvant trastuzumab following chemotherapy, with all these patients being given endocrine therapy. Here, ESR1 is linked to breast carcinoma.